MedTrace Logo

Efficacy of Attention Bias Modification vs. Placebo for Social Anxiety Disorder

NCT07666776 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-06-24

No results posted yet for this study

Summary

This study examines whether a computerized attention-training intervention called attention bias modification (ABM) can reduce symptoms of social anxiety disorder (SAD) in adults, and whether symptom improvement is specifically related to changes in attentional processing or to nonspecific factors such as expectancy and placebo effects.

Conditions

  • Social Anxiety Disorder (SAD)
  • Attention Bias Modification Treatment (ABMT)
  • Placebo Effect

Interventions

BEHAVIORAL

Dot-Probe Attention Bias Modification (ABM)

Participants complete a computerized dot-probe attention training task designed to train attention away from threat-related stimuli. During each trial, angry and neutral facial expressions are presented simultaneously, followed by a probe that consistently appears in the location of the neutral face. Participants complete eight training sessions over four weeks.

BEHAVIORAL

Placebo Training

Participants complete a computerized task matched to the active training condition in duration, structure, and task demands, but without exposure to emotional stimuli or attentional training contingencies. The task is designed to control for nonspecific factors such as expectancy and engagement. Participants complete eight sessions over four weeks.

Sponsors & Collaborators

  • Tel Aviv University

    lead OTHER

Principal Investigators

  • Yair Bar-Haim, PhD · Tel Aviv University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-15
Primary Completion
2026-10-30
Completion
2027-06-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07666776 on ClinicalTrials.gov